Mega Lifesciences (MEGA) Q3 2026 earnings summary

Executive summary

• 9M 2026 sales revenue was 10,672,155 thousand Baht vs 10,483,287 thousand Baht; profit rose to 1,734,480 thousand Baht from 1,334,991 thousand Baht.

• Q3 sales revenue was 3,729,760 thousand Baht vs 3,876,261 thousand Baht; profit increased to 615,337 thousand Baht from 494,208 thousand Baht.

Financial highlights

• 9M basic EPS was Baht 1.99 vs Baht 1.53; Q3 basic EPS was Baht 0.71 vs Baht 0.57.

• 9M profit attributable to parent owners was 1,734,460 thousand Baht vs 1,334,942 thousand Baht.

• 9M total comprehensive income was 1,858,458 thousand Baht vs 1,201,670 thousand Baht, including current-period foreign currency translation gains.

• 9M cost of sales was 5,093,050 thousand Baht vs 5,053,524 thousand Baht; selling expenses rose to 2,130,121 thousand Baht from 1,901,944 thousand Baht.

Key financial ratios and metrics

• Consolidated cash and cash equivalents were 3,449,725 thousand Baht at 30 Sep 2026 vs 4,272,684 thousand Baht at 31 Dec 2025.

• Total assets were 16,171,984 thousand Baht vs 15,759,243 thousand Baht; total liabilities were 5,966,595 thousand Baht vs 5,544,024 thousand Baht.

• Net cash from operating activities was 1,610,951 thousand Baht for 9M, compared with 1,713,767 thousand Baht in 9M 2025.